Practice Areas

Dairy company Fonterra is reportedly challenging a court's refusal to give it certainty over lucrative licence agreements with Bega Cheese as it pursues a sale of its Australian business.

Hungry Jack's has paid over $150,000 in penalties for allegedly breaking the Australian Consumer Law by failing to comply with button battery standards with its 'burping Garfield' kids meal toy.

The lead plaintiff in a class action alleging police conducted thousands of unlawful strip searches at music festivals in NSW has sought $130,000 in damages on the first day of trial against the state. 

Woodside is facing another legal challenge to its $16.5 billion Scarborough gas project, in what an environmental group called a "test case" for how NOPSEMA will assess greenhouse gas emissions from energy projects. 

The former CEO of School Infrastructure NSW directed a $20 million contract to friends -- a former PwC partner and the head of a consulting firm -- without disclosing any conflicts, according to an ICAC inquiry.

A stay of a $37 million 2023 judgment in favour of the company behind an abandoned $185 million development in Gosford NSW against the Australian arm of China's Shanxi Construction Investment Group has been extended.

Seven has gone on the offensive in a lawsuit by former Spotlight producer Taylor Auerbach that alleges the broadcaster breached a settlement deed and defamed him, arguing it was Auerbach who broke the terms of their agreement. 

A judge has signed off on a settlement in a class action by investors in failed advisory firm Linchpin Capital, with insurer AIG paying $12.15 million and forfeiting its right to appeal a liability finding.

Alcoa has won a transfer pricing dispute with the Tax Office, with a tribunal rejecting the ATO's novel argument that Alcoa was not dealing at arm's length in selling alumina to a distributor that bribed Bahraini government officials.

Biopharmaceutical company Amgen has lodged proceedings against generic maker Sandoz, calling for documents related to regulatory approval of a generic version of its top-selling bone disease treatments.